S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
2 Stocks to Benefit from the Aging Population
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Alcoa, Krispy Kreme fall; Williams-Sonoma, Ford rise, Monday, 9/25/2023
Interest rates will stay high 'as long as necessary,' the European Central Bank's leader says
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
Is Hanes Worth More than the Sum of Its Parts?
NASDAQ:ABVC

ABVC BioPharma (ABVC) Stock Forecast, Price & News

$0.94
+0.06 (+6.82%)
(As of 09/25/2023 ET)
Compare
Today's Range
$0.88
$1.03
50-Day Range
$0.88
$5.32
52-Week Range
$0.82
$18.70
Volume
42,323 shs
Average Volume
79,975 shs
Market Capitalization
$3.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ABVC stock logo

About ABVC BioPharma (NASDAQ:ABVC) Stock

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.

ABVC Price History

ABVC Stock News Headlines

How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
ABVC Corporate Update and CEO's Letter to Shareholders
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Why ABVC Biopharma Stock Is Roaring Higher
Why ABVC Biopharma Stock Is Trading Higher
ABVC BioPharma names Patil as new CEO
See More Headlines
Receive ABVC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ABVC BioPharma and its competitors with MarketBeat's FREE daily newsletter.

ABVC Company Calendar

Last Earnings
8/14/2023
Today
9/26/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABVC
Fax
N/A
Employees
19
Year Founded
N/A

Profitability

Net Income
$-16,420,000.00
Net Margins
-1,607.06%
Pretax Margin
-1,495.69%

Debt

Sales & Book Value

Annual Sales
$970,000.00
Book Value
$0.99 per share

Miscellaneous

Free Float
2,410,000
Market Cap
$3.71 million
Optionable
Not Optionable
Beta
0.32
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Eugene Jiang (Age 37)
    Chairman & Chief Bus. Officer
    Comp: $200k
  • Mr. Leeds Chow (Age 34)
    CFO & Principal Accounting Officer
    Comp: $130k
  • Dr. Tsung-Shann Jiang EMBA (Age 69)
    Ph.D., Chief Scientific Officer & Director
    Comp: $200k
  • Dr. Uttam Yashwant Patil Ph.D.
    Chief Exec. Officer













ABVC Stock - Frequently Asked Questions

Should I buy or sell ABVC BioPharma stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ABVC BioPharma in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ABVC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABVC, but not buy additional shares or sell existing shares.
View ABVC analyst ratings
or view top-rated stocks.

How have ABVC shares performed in 2023?

ABVC BioPharma's stock was trading at $6.25 at the start of the year. Since then, ABVC shares have decreased by 85.0% and is now trading at $0.94.
View the best growth stocks for 2023 here
.

Are investors shorting ABVC BioPharma?

ABVC BioPharma saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 19,800 shares, a decline of 29.8% from the August 15th total of 28,200 shares. Based on an average daily trading volume, of 791,400 shares, the days-to-cover ratio is presently 0.0 days. Currently, 1.0% of the shares of the company are short sold.
View ABVC BioPharma's Short Interest
.

When is ABVC BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ABVC earnings forecast
.

How were ABVC BioPharma's earnings last quarter?

ABVC BioPharma, Inc. (NASDAQ:ABVC) issued its quarterly earnings data on Monday, August, 14th. The company reported ($0.68) EPS for the quarter. The business earned $0.01 million during the quarter. ABVC BioPharma had a negative trailing twelve-month return on equity of 477.58% and a negative net margin of 1,607.06%.

When did ABVC BioPharma's stock split?

Shares of ABVC BioPharma reverse split before market open on Tuesday, July 25th 2023. The 1-10 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did ABVC BioPharma IPO?

(ABVC) raised $7 million in an initial public offering (IPO) on Tuesday, August 3rd 2021. The company issued 1,100,000 shares at $6.25 per share.

What is ABVC BioPharma's stock symbol?

ABVC BioPharma trades on the NASDAQ under the ticker symbol "ABVC."

How do I buy shares of ABVC BioPharma?

Shares of ABVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ABVC BioPharma's stock price today?

One share of ABVC stock can currently be purchased for approximately $0.94.

How much money does ABVC BioPharma make?

ABVC BioPharma (NASDAQ:ABVC) has a market capitalization of $3.71 million and generates $970,000.00 in revenue each year. The company earns $-16,420,000.00 in net income (profit) each year or ($3.88) on an earnings per share basis.

How can I contact ABVC BioPharma?

ABVC BioPharma's mailing address is 44370 Old Warm Springs Boulevard, Fremont, CA 94538, United States. The official website for the company is www.abvcpharma.com. The company can be reached via phone at (510)-668-0881.

This page (NASDAQ:ABVC) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -